Vanguard Capital Management
AQST icon

Vanguard Capital Management’s Aquestive Therapeutics AQST Stock Holding History

Vanguard Capital Management’s Portfolio AQST Stock Details AQST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$19.1M Buy
4,584,533
+140,835
+3% +$593K ﹤0.01% 2477
2026
Q1 		$18.4M Buy
+4,443,698
New +$18M ﹤0.01% 2388

Other funds holding AQST

BCM
Bratton Capital Management Fort Worth, Texas $40.8M AUM 25.68% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
SCM
Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return
PBM
Propel Bio Management Los Angeles, California $191M AUM 102.42% 1-Year Est. Return

Vanguard Capital Management's AQST Position: Q2 2026 in Review

Vanguard Capital Management increased its Aquestive Therapeutics (AQST) stake by 3.2% in Q2 2026, buying an estimated $593K and bringing the position to 4,584,533 shares worth $19.1M. The position accounts for ﹤0.01% of the portfolio, ranked #2477.

Vanguard Capital Management first reported a position in AQST in Q1 2026 and has held it in 2 quarters since. 185 funds tracked by Wall St. Rank hold AQST as of Q2 2026.

  • Vanguard Capital Management held 4,584,533 shares of Aquestive Therapeutics worth $19.1M as of Q2 2026.
  • Vanguard Capital Management bought 140,835 Aquestive Therapeutics shares in Q2 2026, an estimated $593K.
  • Aquestive Therapeutics made up ﹤0.01% of Vanguard Capital Management's portfolio in Q2 2026, its #2477 holding.
  • Vanguard Capital Management first reported a position in Aquestive Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 185 funds tracked by Wall St. Rank held Aquestive Therapeutics as of Q2 2026.

Based on Vanguard Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.